Mangoceuticals closes $493K registered direct offering at $0.75/unit, a 74% premium to $0.43 recent close

MANGOCEUTICALS, INC.

Entered Oct. 8, 2026 securities purchase agreement for a registered direct offering of 657,000 shares and warrants to buy 657,000 shares at $0.75 per unit; gross proceeds about $492,750.
Warrants have a $1.00 exercise price, are exercisable immediately, expire five years from issuance, and allow cashless exercise at 1.08x; holder ownership capped at 4.99% or 9.99%.
Offering closed Oct. 9, 2026, priced at $0.75 per unit, an approximately 74% premium to the referenced recent closing price of $0.43; no placement agent, underwriter, or financial advisor was used.
Net proceeds to be used for working capital and general corporate purposes; shares and warrants sold under shelf registration S-3 (No. 333-288039) declared effective June 24, 2025.
Press release also notes Oct. 1, 2026 subsidiary MangoRx IP Holdings received $1.75M of $2.5M strategic commitments for 25% membership interest; remaining $750,000 due by Nov. 28, 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.